Macrogenics (MGNX) Research & Development (2012 - 2026)

Macrogenics (MGNX) has 15 years of Research & Development data on file, last reported at $35.0 million in Q1 2026.

• On a quarterly basis, Research & Development fell 11.9% year-over-year to $35.0 million in Q1 2026; TTM through Mar 2026 was $142.4 million, a 16.63% decrease from a year earlier, with the FY2025 full-year figure at $147.2 million, down 16.94% from the prior year.
• Research & Development for Q1 2026 stood at $35.0 million, up from $34.0 million in the prior quarter.
• Over the last five years, Research & Development for MGNX reached as high as $61.4 million in Q1 2022 and fell as low as $30.1 million in Q3 2023.
• Historically, Research & Development has averaged $43.1 million across 5 years, with a median of $43.2 million in 2023.
• Across the five-year window, Research & Development sank 37.48% in 2023 and surged 34.56% in 2024, its largest moves.
• Year by year, Research & Development stood at $45.7 million in 2022, then increased by 3.72% to $47.4 million in 2023, then fell by 17.87% to $38.9 million in 2024, then declined by 12.64% to $34.0 million in 2025, then increased by 2.94% to $35.0 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $35.0 million in Q1 2026, $34.0 million in Q4 2025, and $32.7 million in Q3 2025.